BOULDER, Colo., Nov. 1 /PRNewswire-FirstCall/ -- Pharmion Corporation announces the live webcast of its 2006 Investor/Analyst Day, to be held in New York on November 2, 2006. Pharmion senior management will discuss a wide variety of subjects including corporate strategy, recent corporate events, clinical development and regulatory overviews, as well as commercial updates and opportunities for each of Pharmion’s marketed products and late-stage product candidates: Vidaza(R) (azacitidine for injectable suspension), thalidomide and satraplatin. Pharmion’s 2006 Investor/Analyst Day will also include an epigenetics primer featuring Vidaza and MGCD0103 and a panel of leading European hematologists discussing the future of myeloma treatment in the EU. The event will conclude with a financial update and summary of key corporate milestones and opportunities.
What: Pharmion 2006 Investor/Analyst Event When: November 2, 2006, 10:00 a.m. ET Where: http://www.videonewswire.com/event.asp?id=36276 How: Live over the Internet -- Simply log on to the web at the address above.
* Those unable to attend can view an archived version for up to 30 days at the same link.
Pharmion is a biotechnology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world’s first approved epigenetic cancer drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company’s website at www.pharmion.com.
Minimum Requirements to listen to broadcast:
The Windows Media Player software, downloadable free from http://www.microsoft.com and at least a 56Kbps connection to the Internet. If you experience problems listening to the webcast, send an E-mail to: webcast@multivu.com.
Pharmion Corporation
CONTACT: Anna Sussman of Pharmion Corporation, +1-720-564-9143,asussman@pharmion.com
